A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6325-6335

  Peterson, David ^a   Lee, James ^a   Lei, Xingye C ^a   Forrest, William F ^a   Davis, David P ^a   Jackson, Peter K ^a   Belmont, Lisa D ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CISPLATIN; PACLITAXEL; POLO LIKE KINASE 1; PROTEIN KINASE; PROTEIN P53; PROTEIN TP53RK; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CHEMOSENSITIZATION; ENZYME ACTIVATION; GENE EXPRESSION; MICROSCOPY; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; SCREENING; THERAPY EFFECT; TREATMENT RESPONSE; VALIDATION STUDY;

ADENOCARCINOMA; APOPTOSIS; CISPLATIN; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HELA CELLS; HUMANS; MITOSIS; PACLITAXEL; PROTEIN KINASES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77955406528     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0015     Document Type: Article

References (52)

1. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008;1785:96-132.
2. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.
3. Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther 2010;9:327-35.
4. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14.
5. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000;6:4610-7.
6. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat Rev Cancer 2007; 7:107-17.
7. Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005;5:127-45.
8. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003;100:2432-7.
9. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999;3: 287-96.
10. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
11. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
12. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
13. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 1998;58:3331-8.
14. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010;30: 640-56.
15. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19:8469-78.
16. Upreti M, Galitovskaya EN, Chu R, et al. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008;283: 35517-25.
17. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/ cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007;26:301-10.
18. Andersen JL, Johnson CE, Freel CD, et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J 2009;28:3216-27.
19. Marash L, Liberman N, Henis-Korenblit S, et al. DAP5 promotes capindependent translation of Bcl-2 and CDK1 to facilitate cell survival during mitosis. Mol Cell 2008;30:447-59.
20. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22.
21. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7:591-600.
22. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-9.
23. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26: 9377-86.
24. Tsui M, Xie T, Orth JD, et al. An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor. PLoS One 2009;4:e7339.
25. Abe Y, Matsumoto S, Wei S, et al. Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem 2001;276:44003-11.
26. Facchin S, Ruzzene M, Peggion C, et al. Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB. Cell Mol Life Sci 2007;64:2680-9.
27. Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006;66:8147-54.
28. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
29. Tang Z, Sun Y, Harley SE, Zou H, Yu H. Human Bub1 protects centromeric sister-chromatid cohesion through Shugoshin during mitosis. Proc Natl Acad Sci U S A 2004;101:18012-7.
30. Gray D, Jubb AM, Hogue D, et al. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res 2005; 65:9751-61.
31. Gray DC, Hoeflich KP, Peng L, et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 2007;7:61.
32. Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;66:999-1006.
33. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
34. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004;64:2502-8.
35. Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67: 237-45.
36. Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998;8:377-85.
37. Ban KH, Torres JZ, Miller JJ, et al. The END network couples spindle pole assembly to inhibition of the anaphase-promoting complex/ cyclosome in early mitosis. Dev Cell 2007;13:29-42.
38. Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11: 498-512.
39. Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep 2006;7: 418-24.
40. Hu D, Valentine M, Kidd VJ, Lahti JM. CDK11(p58) is required for the maintenance of sister chromatid cohesion. J Cell Sci 2007;120: 2424-34.
41. Yokoyama H, Gruss OJ, Rybina S, et al. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. J Cell Biol 2008;180:867-75.
42. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4.
43. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-6.
44. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008;28: 372-412.
45. Sutton D, Diamond M, Faucette M, et al. Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models. AACR Meeting Abstracts 2007;2007:538.
46. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
47. Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008;68:3269-76.
48. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
49. Orth JD, Tang Y, Shi J, et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 2008;7:3480-9.
50. Dumaz N, Meek DW. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999;18:7002-10.
51. Nakagawa K, Taya Y, Tamai K, Yamaizumi M. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol 1999;19:2828-34.
52. Dehan E, Bassermann F, Guardavaccaro D, et al. βTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009;33:109-16.